Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. ACN
3. FFAI
4. PAGP
5. WBD
6. FAN
7. COHR
8. STI
9. PAA
10. BA

Go back to Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
Novavax, Inc. (NASDAQ: NVAX) Delayed: 10.11 --0 (-0%)
Previous Close $10.11    52 Week High $9.23 
Open $10.11    52 Week Low $1.16 
Day High $10.11    P/E N/A 
Day Low $10.11    EPS $-0.30 
Volume 5,922